PPIs Protective for Esophageal Cancer

Patients with Barrettâ€™s esophagus (BE) who are treated with proton pump inhibitors (PPIs) have a significantly decreased risk for progression to high-grade dysplasia or esophageal adenocarcinoma (EAC), a recent systematic analysis presented at the 2014 American Society for Clinical Oncology Gastrointestinal Cancers Symposium showed. http://www.gastroendonews.com/ViewArticle.aspx?d=In%2Bthe%2BNews&d_id=187&i=April+2014&i_id=1048&a_id=26309

AUDIENCES

Caregivers
Friends and Family
General Public
Medical Profession
Patients
Survivors

SUBJECTS

Post Surgical

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino